Skip to main content
About
Management Team
Board of Directors
Scientific Advisory Board
Business Development
Careers
Contact Us
Pipeline
Programs
Sitravatinib (MGCD516)
KRAS G12C Inhibitor (MRTX849)
Posters/Publications
Clinical Trials
Mirati Sponsored Trials
Collaboration Trials
Expanded Access Policy
(Compassionate Use)
Investors
Overview
News Releases
Events & Presentations
Stock Information
Analyst Coverage
Financials & Filings
Corporate Governance
Investor FAQs
IR Contact
Emails Alerts
News Releases
Normal
Press release year list
2019
2018
2017
2016
2015
2014
2013
12/20/2018
Mirati Therapeutics Added To NASDAQ Biotechnology Index
12/10/2018
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
11/29/2018
Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
11/20/2018
Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
11/09/2018
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
11/09/2018
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
11/08/2018
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
11/07/2018
Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
11/06/2018
Mirati Therapeutics Reports Third Quarter Financial Results
11/05/2018
Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
10/30/2018
Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
10/22/2018
Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
10/21/2018
Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
10/15/2018
Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
8/29/2018
Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference
8/16/2018
Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition
8/01/2018
Mirati Therapeutics Reports Second Quarter Financial Results
7/24/2018
Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress
6/25/2018
Mirati Therapeutics Added to Russell 2000® Index
6/11/2018
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/07/2018
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
6/06/2018
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
5/31/2018
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
5/30/2018
Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference
5/07/2018
Mirati Therapeutics Reports First Quarter Financial Results
4/24/2018
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
3/08/2018
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
3/07/2018
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
2/08/2018
Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
1/08/2018
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region